ABSTRACT
Endogenous β cell regeneration could alleviate diabetes, but proliferative stimuli within the islet microenvironment are incompletely understood. We previously found that β cell recovery following hypervascularization-induced β cell loss involves interactions with endothelial cells (ECs) and macrophages (MΦs). Here we show that proliferative ECs modulate MΦ infiltration and phenotype during β cell loss, and recruited MΦs are essential for β cell recovery. Furthermore, VEGFR2 inactivation in quiescent ECs accelerates islet vascular regression during β cell recovery and leads to increased β cell proliferation without changes in MΦ phenotype or number. Transcriptome analysis of β cells, ECs, and MΦs reveals that β cell proliferation coincides with elevated expression of extracellular matrix remodeling molecules and growth factors likely driving activation of proliferative signaling pathways in β cells. Collectively, these findings suggest a new β cell regeneration paradigm whereby coordinated interactions between intra-islet MΦs, ECs, and extracellular matrix mediate β cell self-renewal.
INTRODUCTION
While investigating how vascular endothelial growth factor-A (VEGF-A) regulates islet vascularization, our group previously characterized a mouse model in which signals from the local microenvironment stimulate β cell self-renewal1. In this model, transiently increasing VEGF-A production in β cells (βVEGF-A) induces endothelial cell (EC) expansion and hypervascularization that causes β cell loss; remarkably, islet morphology, capillary network, β cell mass, and function normalize 6 weeks after withdrawal (WD) of the VEGF-A stimulus. This regenerative response is a result of a transient but robust burst in β cell proliferation, which is dependent on VEGF-A-mediated recruitment of macrophages (MΦs). These recruited cells express markers of both pro-inflammatory (M1) and restorative (M2) activation, suggesting a unique regenerative phenotype1–5. Further investigation into the role of various microenvironmental components on β cell proliferation in this model is needed given that this regenerative microenvironment promotes proliferation of human in addition to mouse β cells1.
MΦs are often perceived as damaging to islets due to their role in β cell loss during diabetes6–8, but it is becoming increasingly appreciated that tissue-resident MΦs play important roles in immune surveillance and tissue homeostasis and function in the islet. Mice with compromised MΦ populations during pancreatic development exhibit reduced β cell proliferation, β cell mass, and impaired islet morphogenesis9,10. Furthermore, recent studies have supported the notion that MΦs contribute to β cell regeneration after several types of injury, including surgically induced pancreatitis11 and diphtheria toxin (DT)-mediated apoptosis12. This recent work highlights the importance of understanding how MΦs contribute to β cell proliferation and further defining MΦ phenotype and function in the βVEGF-A model.
In addition to MΦs, ECs are known to participate in tissue repair via activation of the VEGF-A–VEGFR2 pathway, which mediates angiocrine factor production and promotes local cell renewal and regeneration13–16. There is a precedent for ECs facilitating tissue repair by influencing MΦ activation toward a restorative, M2-like phenotype4. Because vasculature is essential for normal islet function, understanding signals that govern EC homeostasis and the effects of ECs on neighboring cell populations is crucial for maintaining and restoring islet health. Signaling between ECs and the pancreatic epithelium is critical for establishing islet vasculature and β cell mass during development, and in mature islets ongoing signaling between endocrine and ECs is required to maintain the capillary network through which endocrine cells receive adequate nutrition and oxygen and can rapidly sense and secrete hormones17–19. The vascular basement membrane is also the primary component of the intra-islet extracellular matrix (ECM) and acts as a reservoir for growth factors and other signaling molecules important for β cell differentiation, function, and proliferation20–23. In the βVEGF-A model, ECs may affect the regenerative process indirectly by promoting MΦ recruitment and activation, altering ECM composition and signaling, and/or by directly influencing β cell proliferation.
Here we deconstructed the complex in vivo islet microenvironment in the βVEGF-A model and show that β cell self-renewal is mediated by coordinated interactions between recruited MΦs, intra-islet ECs, and the ECM (Figures 1, S1). To isolate the roles of MΦs and ECs in this model we removed MΦs from the islet microenvironment (Figures 1, S1; experimental scheme A) and inactivated VEGFR2 signaling in ECs to discern the effects of proliferative or quiescent ECs on β cell proliferation (Figures 1, S1; experimental schemes B and C). Since the βVEGF-A islet microenvironment is a complex in vivo system involving dynamic changes in islet cell composition, we also identified regenerative signals by performing transcriptome analysis (Figures 1, S1; experimental scheme D) of purified islet cell populations including β cells, ECs, and MΦs over the course of β cell loss and recovery. Based on previous work1,16 we predicted that either MΦ depletion (clodronate) or loss of VEGFR2 signaling in ECs would perturb MΦ recruitment and polarization and impair β cell regeneration. Indeed, we found that MΦ depletion suppressed the transient burst in β cell proliferation leading to reduced recovery of β cell mass.
In addition, VEGFR2-mediated signaling in intra-islet ECs was necessary for maximal MΦ recruitment and M2-like phenotype activation. Surprisingly, VEGFR2 ablation in quiescent ECs during the period of β cell recovery accelerated islet vascular regression leading to increased β cell proliferation while MΦ phenotype and number was unchanged. Transcriptome analysis during β cell death and recovery revealed intricate changes in expression of growth factors, integrins, and matrix remodeling enzymes in all three cell types, suggesting that ECM remodeling and activation of ECM-associated molecules within the islet microenvironment play critical roles in β cell self-renewal. Taken together, our results indicate that both MΦs and intra-islet ECs provide crucial microenvironmental cues to cooperatively promote β cell regeneration.
RESULTS
We previously developed the βVEGF-A model, which allows for Dox-induced, β cell-specific overexpression of VEGF-A causing rapid intra-islet EC expansion, widespread β cell loss, and MΦ recruitment to islets from a pool of circulating monocytes1. When Dox is removed and VEGF-A levels normalize, ECs return to baseline levels, but MΦs persist in the islet microenvironment, and β cells undergo a transient but robust proliferation that leads to β cell mass restoration (Figure 1).
Chemical depletion of macrophages in βVEGF-A islets inhibits β cell proliferation
To dissect pathways and signaling molecules in the islet microenvironment required for β cell recovery, we first employed clodronate-mediated MΦ depletion which impacts both infiltrating and islet resident MΦs. Clodronate is an ATP/ADP translocase inhibitor, and when packaged into liposomes it is selectively taken up by MΦs due to their phagocytic properties and causes apoptosis. We treated βVEGF-A mice with either control or clodronate liposomes starting one day before VEGF-A induction and continuing for one week after VEGF-A normalization (Figure 2A). Compared to control, clodronate treatment reduced circulating CD11b+ Ly6G− monocytes by 50% within 24 hours (Figure 2B,No Dox, and Figure S2) and reduced the MΦ population in islets by 94% one week after VEGF-A induction (Figure 2C and 2D, 1wk Dox). MΦ depletion was maintained during VEGF-A normalization, with 86% fewer MΦ in islets from clodronate-treated βVEGF-A mice one week after Dox withdrawal (Figure 2C and 2D, 1wk WD). VEGF-A induction in clodronate-treated mice led to increased EC area (Figures 2C and 2E) and β cell loss (Figures 2B and 2F) comparable to βVEGF-A mice treated with control liposomes, thus demonstrating that clodronate treatment and MΦ depletion did not influence intra-islet EC expansion and hypervascularization-induced β cell loss. In contrast, MΦ depletion significantly impaired β cell proliferation during the recovery period (8.5 vs. 2.1%, p<0.001; Figure 2G) and resulted in reduced β cell area compared to controls after 6 weeks of VEGF-A normalization (Figure 2F), demonstrating that MΦs are required for the regenerative response in βVEGF-A islets. Interestingly, β cell area is slightly but significantly increased one week after Dox withdrawal (Figure 2F, 1wk WD) in clodronate-treated βVEGF-A mice before ultimately the impaired β proliferation leads to reduced β cell area 6 weeks after VEGF-A normalization. This finding suggests that MΦs play an important role in islet remodeling and composition in βVEGF-A mice separate from their effect on β cell proliferation, most likely through their function as phagocytes.
Proliferative ECs are required for MΦ polarization and maximal MΦ recruitment
To investigate the contribution of ECs to β cell loss and recovery in the βVEGF-A model, we first created a mouse line in which VEGFR2, which is enriched in ECs of islet capillaries and the main transducer of VEGF-A signal in islets, is inactivated by tamoxifen (Tm)-inducible Cre-mediated excision in ECs. We initially tested the EC-SCL-CreERT transgene24, which contains a 5’ endothelial enhancer for the stem cell leukemia (SCL) transcription factor, and although Cre activity was confirmed in islet ECs using the Gt(ROSA)26Sortm1Sor reporter strain25, VEGFR2 expression was unchanged in EC-SCL-CreERT; VEGFR2fl/fl mice (data not shown). Fortunately, were able to obtain the Cad5-CreERT2 line26 and achieved efficient EC-specific VEGFR2 knockdown in Cad5-CreERT2; VEGFR2fl/fl (VEGFR2iΔEC) mice. Pancreata harvested after 3 doses of Tm were evaluated to confirm VEGFR2 ablation (Figures S3A and S3B) without significant changes in islet capillary density or size (Figures S3C and S3D) or basal β cell proliferation (Figure S3E), indicating that acute loss of VEGFR2 signaling in ECs is not detrimental to adult islet vascular homeostasis or β cell proliferation. A similar observation was made previously when VEGF-A was acutely inactivated in adult β cells18. Next, we crossed VEGFR2iΔEC mice with the existing βVEGF-A line to effectively perturb VEGF-A–VEGFR2 signaling in ECs at various time points during β cell loss and recovery. To control for any possible effects of Tm administration on compensatory β cell proliferation27, we treated all mice with Tm and designated Cre-negative (βVEGF-A; VEGFR2fl/fl) mice as controls to represent intact VEGFR2 signaling by ECs.
To determine the effect of proliferative ECs on MΦ recruitment and polarization, Tm was administered to knock down VEGFR2 (R2) in ECs prior to VEGF-A induction in β cells (Figures 4A and S4A). VEGF-A was induced in both control βVEGF-A; R2fl/fl and βVEGF-A; R2iΔEC genotypes, with efficient knockdown of VEGFR2 in the latter (Figure S4B). As expected, VEGF-A induction caused a 7% EC expansion and associated 16% β cell loss per islet area in βVEGF-A; R2fl/fl controls, whereas EC and β cell area did not change in βVEGF-A; R2iΔEC mice (Figures 3B-D). These results indicate that activation of VEGFR2 signaling in ECs by acute elevation of VEGF-A in the islet microenvironment is essential for islet hypervascularization and leads to β cell loss.
Inactivation of VEGFR2 signaling in ECs significantly reduced, but did not completely prevent MΦ recruitment to βVEGF-A; R2iΔEC islets compared to βVEGF-A; R2fl/fl controls (5.0 vs. 6.3% per total islet area, respectively; p<0.05) (Figures 3E and 3F). This suggests that MΦ infiltration can occur in response to VEGF-A alone, which is consistent with the fact that VEGF-A can mediate monocyte recruitment through VEGFR1 activity28,29. Still, the proliferative EC environment (intact VEGF-A–VEGFR2 signaling and β cell loss) leads to maximal MΦ recruitment. Interestingly, a subset of infiltrating MΦs in control islets expressed the M2-like marker CD206 (Mrc1), which is normally made only by exocrine MΦs30,31, while infiltrating MΦs in βVEGF-A; R2iΔEC islets remained CD206− (Figures 3E and 3G). This observation suggests that VEGFR2 signaling in proliferative ECs and/or β cell loss promotes MΦ polarization to an M2-like phenotype.
VEGFR2 inactivation in quiescent ECs accelerates EC regression, enhancing β cell recovery
To investigate the role of VEGFR2 signaling in quiescent ECs during β cell recovery, VEGF-A-mediated EC proliferation and β cell loss was first induced with 3-day Dox treatment in βVEGF-A; R2iΔEC mice and controls, followed by 7 days of Dox withdrawal to allow VEGF-A to normalize and ECs to return back to quiescence (Figures 4A, S5A). Islet phenotype and β cell proliferation was assessed after 7 days of VEGF-A normalization (7d WD) and subsequently 2 days post-Tm treatment to inactivate VEGFR2 (9d WD). VEGF-A-induced EC expansion, β cell loss, and MΦ infiltration occurred in both genotypes, with no difference between the two groups at 7d WD prior to VEGFR2 inactivation (Figures 4B-E). As expected, VEGF-A expression continued to decline during Dox withdrawal and VEGFR2 was efficiently inactivated in βVEGF-A; R2iΔEC mice within 48 hours of a single 4-mg Tm injection (Figure S5B). Surprisingly, unlike under normal homeostatic conditions (Figure S3), VEGFR2 inactivation in βVEGF-A; R2iΔEC mice significantly accelerated islet EC regression compared to controls (Figure 4D) without changes in MΦ phenotype (Figure S5C) and number (Figure 4C), suggesting that neither MΦ retention nor polarization at this stage of β cell recovery are dependent on VEGFR2 signaling in quiescent ECs.
Since VEGFR2 inactivation in quiescent ECs of βVEGF-A; R2iΔEC mice leads to a relatively rapid EC decline after Tm treatment (9d WD), we next evaluated the islet vascular regression by visualization of collagen IV, a major component of the islet ECM32,33 generated by intra-islet ECs. This study revealed that regressing islet capillaries leave behind vascular “casts” of ECM that are no longer associated with intact ECs (Figure 4F,9d WD). Even more surprising was our finding that this accelerated decline in islet ECs enhances β cell proliferation at 9d WD (Figure 4G). We hypothesize that in contrast to β cell homeostasis, the regression of quiescent ECs during the β cell recovery phase stimulates release of growth factors from degraded ECM, thereby promoting β cell proliferation (Figure 4H).
Identifying interactions between β cells, ECs, and MΦs in the βVEGF-A islet microenvironment
Our prior studies in the βVEGF-A model localized the stimulus for β cell proliferation to the islet microenvironment, ruling out any contribution from circulating factors that might reach the pancreas1. With key roles established for both MΦs and ECs in this system, we next sought to identify potential mechanisms and signaling pathways coordinating cell-cell and cell-matrix interactions. To do this we isolated βVEGF-A islets at baseline (No Dox) and during the course of VEGF-A induction (1wk Dox) and normalization (1wk WD) and purified islet populations of β cells, ECs, and MΦs at each of these time points for transcriptome analysis (Figures 5A, S6A and S6B).
All of the nine sample types analyzed (3 cell types per each of 3 time points) demonstrate distinct transcriptional profiles, reflecting a high degree of uniqueness among three cell types and significant temporal changes in gene expression within each cell type (Figures S6C-E). By hierarchical clustering, the highest correlations were observed within one cell type across different time points; for example, β cells at No Dox are more similar to β cells at 1wk Dox and 1wk WD than they are to MΦs or ECs at any time point. Of the β cell samples, regenerative β cells (1wk WD) are more similar to stressed β cells (1wk Dox) than quiescent β cells (No Dox); in contrast, regenerative MΦs (1wk WD) are more similar to resident MΦs (No Dox) than to those recruited upon VEGF-A induction (1wk Dox), and quiescent ECs following VEGF-A normalization (1wk WD) are more similar to quiescent ECs at baseline (No Dox) than to proliferative ECs (1wk Dox) (Figure S6D).
With the induction of VEGF-A (1wk Dox), all cell populations increase expression of growth factors, matrix remodeling enzymes involved in tissue repair and matrix degradation (MMPs, ADAMs, ADAMTSs), as well as cell adhesion molecules involved in cell-matrix and cell-cell interactions (ICAM1, VCAM1, selectins), many of which remain elevated during β cell regeneration (1wk WD) (Figure S7A). Pathway analysis shows a high degree of cellular motility (Figure S7B), and extracellular organization and cell adhesion processes are significantly enriched in all cell types during β cell recovery (Figure S8).
Infiltrating MΦs show elevated expression of both pro-inflammatory and pro-regenerative markers during periods of initial monocyte recruitment (1wk Dox) and β cell regeneration (1wk WD). Pro-inflammatory genes like Il12b and Il1a are upregulated at 1wk Dox, while M2 markers such as Ptgs1 and Retnla are upregulated and/or remained elevated at 1wk WD (Figure S7A). Upregulation of chemokines and cytokines by MΦs and corresponding increase in expression of receptors (e.g., Cxcr4, Il12rb2) by β cells suggests crosstalk between the two cell types and potential phenotypic effects on β cells in addition to MΦs. Similarly, increased growth factor expression in ECs and MΦs appears in concert with increased expression of growth factor receptors in β cells (Figure S7A).
At the peak of regeneration (1wk WD), β cells highly express integrins and other molecules that sense and respond to changes in the extracellular milieu (Figure 5B). Activation of integrin-mediated signaling and the integrin-linked kinase pathway were accompanied by increases in PI3K/Akt and MAPK signaling genes (Figures S8A and 5C), many of which are known modulators of β cell proliferation34–37. Transcriptional activators Cdk6 and Foxm1 are initially upregulated more than 3-fold compared to baseline, followed by downregulation of suppressor Cdkn2c (p18) specifically during β cell recovery, consistent with previous studies of both mouse and human β cells38–40. Creb5 and Ets1 are notably increased as well. Collectively, these data provide evidence for a model where β cell proliferation is largely driven through MΦ–EC–β cell paracrine signaling, ECM remodeling, and cell-matrix interactions (Figure 6).
DISCUSSION
Adult β cells have a very limited proliferative capacity and signals regulating this process are incompletely understood. The complexity of the islet microenvironment and difficulty modeling this complexity in vitro often constrains investigation of β cell proliferation to reductionist approaches, removing components of the in vivo environment known to contribute to the establishment and maintenance of β cell mass and thereby limiting the utility of these studies. Here we utilized the βVEGF-A mouse model1 in which signals from the local islet microenvironment, including β cells, ECs, and MΦs, promote proliferation of human as well as mouse β cells. To dissect how these microenvironmental components influence β cell loss and recovery within the context of this complex and dynamic in vivo model, we developed new experimental tools to intricately modulate EC and MΦ populations and their signaling within the islet. These tools, coupled with transcriptional analysis of temporal changes in gene expression patterns of β cells, ECs, and MΦs, allowed us to gain important insight into the cell-cell and ECM-mediated signaling in this model, which work in concert to promote β cell proliferation (Figure 6).
Role of macrophages
Our transcriptome analysis suggested that MΦ recruitment to islets is facilitated not only by VEGF-A signaling but also by increased expression of cell adhesion molecules on both MΦs and ECs, as well as increased production of chemokines and cytokines from MΦs already in the islet microenvironment41. By specifically depleting MΦs in βVEGF-A mice using clodronate liposomes, we demonstrated that MΦs are required for β cell regeneration in the islet microenvironment. These recruited MΦs have a unique hybrid phenotype: they express markers of both classical pro-inflammatory (M1) activation as well as alternative (M2) activation promoting tissue repair and regeneration. Though MΦ-derived cytokines and chemokines can exacerbate β cell stress42,43, the comparable β cell loss in MΦ-depleted and control islets suggests that MΦs do not promote β cell apoptosis in this model. Instead, MΦs downregulate key pro-inflammatory cytokines (e.g., Tnf, Il6) at 1wk WD, concomitant with β cell proliferation. Their phenotypic profile at this stage is most reminiscent of phenotyping subtypes “M2a” (high expression of scavenger and phagocytic receptors like Retnlb/Fizz2, Ym1, and Mrc1; secretion of profibrotic and trophic factors like fibronectin, IGF, and TGFβ) and “M2c” (associated with removal of apoptotic cells)44–46. This phagocytic phenotype is consistent with our finding that MΦs at this time point (1wk WD) likely have an effect on islet remodeling and composition separate from their effect on β cell proliferation. Together, these data suggest a phenotypic shift in MΦs that facilitates β cell recovery and return to homeostasis in the islet, in line with an increasing number of studies observing tissue-restorative effects of MΦs triggered in various β cell injury models11,12,47. Further studies will be necessary to clarify the specific signals that regulate the phenotypic shift and define the cues that govern their withdrawal.
Role of endothelial cells
Regulated EC-derived signals are necessary for pancreatic and islet development17,48–50, optimal adult β cell function18, and islet revascularization after transplantation51–54. In addition, ECs and VEGFR2 signaling have been previously implicated in organ regeneration13,16. For example, during liver regeneration, sinusoidal ECs appear to have a biphasic effect in mediating hepatic reconstitution; proliferative angiogenesis of sinusoidal ECs inhibits hepatocyte self-renewal, whereas quiescent sinusoidal ECs stimulate hepatic regeneration13. To determine the role of proliferative and quiescent ECs in β cell loss and recovery, we generated a compound βVEGF-A model with inducible VEGFR2 inactivation (βVEGF-A; VEGFR2iΔEC) that allowed us to modulate VEGF-A–VEGFR2 signaling in ECs.
Our studies show that intact VEGFR2 signaling is required for the proliferative angiogenesis of islet endothelium, which ultimately results in β cell loss. Although transcriptome analysis did not reveal specific signals produced by proliferating ECs that would lead to β cell apoptosis during VEGF-A induction, there are significant changes in expression of matrix remodeling enzymes and cell adhesion molecules. Based on the importance of cell-matrix interactions in β cell survival in vitro20,55, we hypothesize that ECM changes associated with rapidly expanding endothelium likely contribute to β cell loss in the βVEGF-A system. In addition, we show that intact VEGFR2 signaling is necessary for accumulation of intra-islet MΦs expressing CD206, a marker of an M2 phenotype. This observation is consistent with MΦ activation by EC-derived cues in the context of acute injury, a phenomenon that has been noted in numerous tissues56–58. Furthermore, a similar M2 phenotype (high IL-10, CD206) was shown to be required for β cell regeneration after DT-mediated ablation12, and elsewhere CD206 has been linked to increased expression of Tgfb1 and Egf 59 and promotion of β cell proliferation via a Smad7-cyclin pathway11.
In contrast to lung and liver regeneration13,16, VEGFR2 inactivation in quiescent ECs (1wk WD) resulted in accelerated β cell recovery, which is associated with rapid islet capillary regression, leaving behind vascular “casts” of ECM components. We postulate that β cell proliferation is promoted by release of growth factors from degraded ECM. Though ECs are no longer expanding at the 1wk WD time point, islets still contain quite extensive capillary networks that might be sustained by the residual extracellular VEGF-A we observed, as well as possibly other growth factors. Interestingly, VEGFR2 inactivation during β cell homeostasis does not impact β cell proliferation and islet capillary morphology. It will be important to assess the role of quiescent ECs and VEGFR2 signaling in other β cell injury models in the future. In addition, these findings highlight that ECs have different roles in different tissues and during various physiologic and pathologic stressors.
Role of extracellular matrix and integrated cellular interactions in β cell proliferation
By deconstructing the contributions of the cellular components of the islet microenvironment of βVEGF-A mice, we were able to uncover a role for ECM remodeling and signaling in β cell proliferation. MΦs, ECs, and β cells all show transcriptional regulation of integrin receptors and ECM remodeling enzymes, some of which have been shown previously to affect β cell proliferation22,60–62. In addition to shaping cell-matrix signaling, ECM reorganization can also lead to the release and/or activation of matrix-sequestered growth factors63–66. This is particularly relevant given the temporal increase of growth factor receptor expression in β cells during VEGF-A induction and normalization, suggesting heightened β cell responsiveness to signals from the rapidly remodeling ECM as VEGF-A normalizes. Together, these data provide evidence that ECM-bound growth factors released during EC regression promote β cell proliferation.
Remodeling of extracellular milieu can also influence MΦ phenotype67,68, though more work is required to define specific signaling pathways that regulate this process in the pancreas. However, our transcriptome data provides evidence that both MΦs and ECs are quite attuned to their rapidly changing environment, with integrins and cell adhesion molecules being some of the most dynamically regulated genes in both cell types. Changes in these molecules are likely regulating MΦ recruitment and/or polarization69–72, which may explain the phenotypic shift that happens between MΦ recruitment (occurring rapidly in response to VEGF-A) and the appearance of β cell proliferation (during VEGF-A normalization).
It is also possible that β cells undergo intrinsic changes heightening their sensitivity to extracellular signals, supported by the observation that ECs and MΦs increase expression of several growth factors known to promote β cell proliferation (IGF-1, PDGF, and CTGF)37,73–75 while β cells simultaneously upregulate expression of corresponding receptors (Igf1r, Pdgfr).
Signaling cascades activated by integrins and growth factors exhibit extensive downstream crosstalk and protein activity that makes it difficult to determine pathway activation status based solely on gene expression. Nonetheless, we did observe transcriptional changes to components of the PI3K/Akt, PLC, and MAPK pathways, as well as upregulation of transcription factors regulated by the MAPK pathway34–37 suggesting that the cell-cell and cell-ECM interactions may converge on the activation of these pathways leading to β cell proliferation. We therefore propose a model in which coordination of growth factors – whose bioavailability is likely modulated by ECs and MΦs – together with increased integrin signaling promotes activation of pro-proliferative pathways in surviving β cells during VEGF-A normalization to ultimately restore β cell mass (Figure 6).
Recognizing the key role of cellular and extracellular components of the islet microenvironment on β cell development, function, and homeostasis is critical to further our understanding of signals regulating adult β cell proliferation. Islet microenvironmental signaling in the βVEGF-A system promotes human β cell proliferation1, which prompted us to develop new strategies to disentangle the roles of various microenvironmental components in this regenerative process. However, moving forward it will be important to further explore the mechanisms and combination of specific cytokines, growth factors, and other microenvironmental signals that activate and regulate relevant mitogenic signaling pathways in human β cells. Overall, these studies highlight the importance of developing innovative approaches to examine β cells in vivo in order to more completely understand the complex microenvironmental factors regulating β cell function and regeneration.
METHODS
Mouse Models
All animal studies were approved by the Institutional Animal Care and Use Committee at Vanderbilt University Medical Center, and animals were kept in facilities monitored by the Vanderbilt University Division of Animal Care on a 12 hour light/12 hour dark schedule with unrestricted access to standard chow and water. Mouse models and abbreviations used to describe them are summarized in Table S2.
RIP-rtTA; TetO-VEGF (βVEGF-A) mice
The original bitransgenic mice with doxycycline (Dox)-inducible β-cell-specific overexpression of human VEGF-A165 (abbreviated βVEGF-A) were generated by crossing RIP-rtTA male mice and TetO-VEGF female mice, both on a C57BL/6 background76–80. These mice were generously provided by Dr. Shimon Efrat of Tel Aviv University and Dr. Peter Campochiaro of Johns Hopkins University, respectively. In this βVEGF-A model the rat Ins2 promoter drives expression of the tetracycline-responsive rtTA transactivator specifically in pancreatic β cells. Upon exposure to Dox, the rtTA transactivator binds the tetracycline operator (TetO), driving expression of human VEGF-A165 in β-cells. Details of Dox preparation and administration are included below.
Cd5-CreER; VEGFR2fl/fl (VEGFR2iΔEC) mice
Mice with Tamoxifen (Tm)-inducible EC-specific knockout of VEGFR2 (abbreviated VEGFR2iΔEC) were generated by crossing Cd5-CreER male mice and VEGFR2fl/fl female mice (see Table S3, crosses A1-A2). Heterozygous VEGFR2fl/wt mice on a C57BL/6 background were obtained from Jackson Laboratories (stock #018977) and bred to create a homozygous VEGFR2fl/fl line. Frozen sperm from the Cd5-CreER line26 was generously provided by Dr. Yoshiaki Kubota of Keio University, and in vitro fertilization (IVF) was performed by the Vanderbilt Genome Editing Resource using female C57BL/6 mice (Jackson Laboratories, stock #000664). In the VEGFR2iΔEC model loxP sites were inserted flanking VEGFR2 exon 3, and the Cdh5 (VE-cadherin) promoter drives expression of Tm-inducible Cre recombinase in vascular ECs. Upon exposure to Tm, Cre recombinase translocates to the nucleus, excising VEGFR2 exon 3 through Cre-loxP recombination and subsequently preventing VEGFR2 expression in ECs. Details of Tm preparation and administration are described below.
βVEGF-A; VEGFR2iΔEC mice
To generate an inducible model of EC-specific knockdown of VEGFR2 in βVEGF-A mice, Cd5-CreER and VEGFR2fl/fl mice were crossed with RIP-rtTA and TetO-VEGF transgenic mice as outlined in Table S3. The final cross produced both βVEGF-A; VEGFR2iΔEC mice as well as Cre-negative sibling controls (βVEGF-A; VEGFR2fl/fl). Due to the inefficient induction of VEGF-A in female mice (the single copy of the TetO transgene is subject to × chromosome inactivation), only male mice were used for experiments.
βVEGF-A; MIP-GFP mice
To enable fluorescence-activated cell sorting (FACS) of pancreatic β cells from βVEGF-A mice, a transgene was separately introduced into the βVEGF-A mouse model by crossing MIP-GFP mice on a C57BL/6 background81 (Jackson Laboratories, stock #006864) with RIP-rtTA and Tet-O-VEGF-A mice (abbreviated βVEGF-A; MIP-GFP). In these mice, the mouse Ins1 promoter drives green fluorescent protein (GFP) expression in β cells.
DNA extraction and genotyping
Mouse models used in our breeding schemes were maintained by genotyping using the primers and PCR conditions listed in Table S4. DNA was extracted and PCR reactions were performed with tail snips from mice as described previously1. Thermal cycler conditions listed in Table S4 were used to amplify DNA before resolving on agarose gels with 100 ng/ml ethidium bromide in 1X Tris/Borate/EDTA (TBE) buffer as indicated.
Compound preparation and administration
VEGF-A transgene expression was activated in βVEGF-A mice by Dox administration (5 mg/ml) in light-protected drinking water containing 1% Splenda® for a period of 3-7 days. VEGFR2 knockdown was induced in VEGFR2iΔEC mice by subcutaneous injection of 4 mg Tm (20 mg/ml; 200 μl). Tm (20 mg/ml) was prepared fresh in filter-sterilized corn oil the day before each injection and allowed to dissolve overnight on a shaker at room temperature, protected from light. Vetbond tissue adhesive (3M) was used to seal injection sites to prevent oil leakage. Clodronate-mediated macrophage depletion in βVEGF-A mice was accomplished by injecting 150-200 μl clodronate liposomes (5 mg/ml; Clodrosome) retro-orbitally every other day for a 1-2 week period (4-8 total injections). Liposome injections began one day before Dox administration and continued for 1 week after in mice harvested at later time points. Control liposomes with the same lipid composition (Clodrosome) were administered to βVEGF-A mice using the same route, volume, and schedule. Mice receiving liposome injections were supplemented with Transgenic Dough Diet (21.2% protein, 12.4% fat, 46.5% carbohydrate; BioServ) throughout the course of the experiment.
Glucose measurements
Random (non-fasted) plasma glucose levels were measuring by obtaining whole blood from nicked tail veins using an Accu-chek glucose meter (Roche Diagnostics) calibrated according to the manufacturer’s instructions.
Tissue Collection and Fixation
Mouse pancreata were collected from anesthetized mice prior to cervical dislocation. Organs were washed in ice-cold 10 mM phosphate buffered saline (PBS), then fat and other excess tissue was removed before pancreata were weighed and processed. Fixation was performed in 0.1 M PBS containing 4% paraformaldehyde (Electron Microscopy Sciences) for 2-3 hours on ice with mild agitation, then organs were washed in four changes of 0.1 M PBS over 2 hours and equilibrated in 30% sucrose/0.01 M PBS overnight. After blotting to remove excess sucrose, tissues were mounted in Tissue Tek cryomolds filled with Tissue-Plus Optimal Cutting Temperature (OCT) compound (VWR Scientific Products). Tissue molds were placed on dry ice until the OCT was set, then stored at −80°C. Tissues were sectioned from 5-10 μm thick on a Leica CM1950 cryostat (Leica) and these cryosections were attached to Superfrost Plus Gold slides (ThermoFischer Scientific).
Immunohistochemistry, Imaging, and Analysis
Immunohistochemical analysis was performed on serial 8-10 μm pancreatic cryosections as described previously1,18. Briefly, tissue permeabilization was conducted using 0.2% Triton-X in 10nM PBS and blocking using 5% normal donkey serum in 10mM. Primary and secondary antibody incubations (listed in Table S5) were performed in buffer with 0.1% Triton-X and 1% BSA and nuclei were counterstained with DAPI. Slides were mounted using SlowFade Gold antifade reagent (Invitrogen Molecular Probes) and sealed with fingernail polish prior to imaging.
Digital images were acquired with a Leica DMI6000B fluorescence microscope equipped with a Leica DFC360FX digital camera (Leica), a laser scanning confocal microscope (Zeiss LSM510 META or LSM880, Carl Zeiss), and a ScanScope FL (Aperio). Image analysis was performed using MetaMorph 7.7 software (Molecular Devices), ImageScope software (Aperio), or HALO software (Indica Labs).
For analysis of islet composition, images of entire pancreatic sections were captured at 20x magnification using a ScanScope FL system. Islet area was annotated manually based on insulin staining, and HALO algorithms were used to calculate area of β cells (Insulin+), ECs (CD31+), and MΦs (Iba1+). For β cell proliferation, cells were deemed positive for Ki67 only when at least 75% of the nucleus was surrounded by insulin+ cytoplasm.
Flow Cytometry and Cell Sorting
Flow analysis and sorting was performed in collaboration with the Vanderbilt Flow Cytometry Core. Peripheral blood (50-100 μl) was collected from the retro-orbital sinus of βVEGF-A mice using heparinized capillary tubes 24 hours after beginning liposome injections to evaluate depletion of circulating monocytes. Blood was incubated for 3-5 minutes at 37°C with 1 ml warmed, filter-sterilized erythrocyte lysis buffer (8.26 g ammonium chloride, 1 g potassium bicarbonate, and 0.38 g EDTA in 1 L Milli-Q water). Cells were pelleted by centrifuging at 1800 rpm for 2-3 minutes at 4°C and supernatant discarded. Incubation with erythrocyte lysis buffer was repeated, and then cells were washed with 1 ml FACS buffer (2 mM EDTA and 2% FBS in 10 mM PBS) prior to antibody incubation. Blood from WT mice was collected for antibody compensation controls.
Isolated islets from βVEGF-A; MIP-GFP mice handpicked in Clonetics EGM MV Microvascular Endothelial Cell Growth Medium (Lonza) were washed 3 times with 2 mM EDTA in 10 mM PBS and then dispersed by incubating with Accutase (Innovative Cell Technologies) at 37°C for 10 minutes with constant pipetting. Accutase was quenched with EGM MV media, and then islet cells were washed twice with the same media and counted using a hemocytometer prior to antibody incubation. Anti-rat Ig, κ CompBead Plus Compensation Particles (BD Biosciences) and EasyComp Fluorescent Particles, GFP (Spherotech) were used as single color compensation controls for islet cell sorts.
Peripheral blood and islet cells prepared as described above, and anti-rat Ig compensation particles were incubated for 15-20 minutes at 4°C with fluorophore-conjugated antibodies in FACS buffer followed by one wash with FACS buffer. All antibodies for flow cytometry and their working dilutions are listed in Table S5. Prior to analysis or sorting, either propidium iodide (0.05 μg/100,000 cells; Invitrogen Molecular Probes) or DAPI (0.25 μg/1,000,000 cells; Invitrogen Molecular Probes) was added to samples for non-viable cell exclusion. Flow analysis was performed using an LSRFortessa cell analyzer (BD Biosciences) and a FACSAria III cell sorter (BD Biosciences) was used for FACS. Analysis of flow cytometry data was completed using FlowJo 7.6.5-10.2.1 (FlowJo LLC).
RNA Isolation, Sequencing, and Analysis
Sorted islet-derived cells (8,000-400,000/sample) were added to 200-400 μl lysis/binding solution in the RNAqueous micro-scale phenol-free total RNA isolation kit (Ambion). Trace contaminating DNA was removed with TURBO DNA-free (Ambion). RNA quality control quantification was performed using a Qubit Fluorometer (Invitrogen, Carlsbad, CA) and an Agilent 2100 Bioanalyzer. All RNA samples had an RNA integrity number (RIN) ≥5.0. RNA was amplified using the Ovation system (NuGen Technologies) according to standard protocol. Amplified cDNA was sheared to target 300bp fragment size and libraries were prepared using NEBNext DNA Library Prep (New England BioLabs). 50bp Paired End (PE) sequencing was performed on an Illumina HiSeq 2500 using traditional methods82,83. Raw reads were mapped to the reference mouse genome mm9 using TopHat v2.084and aligned reads were then imported onto the Avadis NGS analysis platform (Strand Scientific). Transcript abundance was quantified using the TMM (Trimmed Mean of M-values) algorithm85,86. Samples were compared by principle component analysis (PCA) and hierarchal clustering analysis. A minimum expression cutoff (normalized expression ≥20 at one or more time points) was applied before determining differential expression between samples, which was calculated on the basis of fold change (cutoff ≥2 or ≤−2) with p-values estimated by z-score calculations (cutoff 0.05) as determined by the Benjamini Hochberg false discovery rate (FDR) method87. Differentially expressed genes were further analyzed through Ingenuity Pathway Analysis (IPA, Qiagen) and Gene Ontology (GO) analysis using DAVID88. RNA quality control, amplification, sequencing, and analysis were performed in collaboration with the Genomic Services Laboratory at HudsonAlpha Institute for Biotechnology.
Statistical Analysis
Prism software (GraphPad) was used to perform all statistical analyses for immunohistochemistry. In all experiments manipulating MΦs and ECs, control and experimental groups were compared at each time point using an unpaired t test. For analysis of proliferative ECs, unpaired t tests were also used to compare baseline (No Dox) and VEGF-A induction (3d Dox) time points within each group. For analysis of quiescent ECs, a one-way analysis of variance (ANOVA) was used to analyze time points within each group, followed by Tukey’s multiple comparison test to compare each time point with baseline (No Dox). Unless otherwise noted, data are expressed as mean + standard error of mean (SEM). Statistical analysis of RNA-sequencing data is described above (see RNA Isolation, Sequencing, and Analysis).
AUTHOR CONTRIBUTIONS
Conceptualization, D.C.S., K.I.A., M.B., and A.C.P.; Methodology, D.C.S., K.I.A., M.B., and A.C.P.; Investigation, D.C.S., K.I.A., T.M.R., A.H., Z.K., R.A., G.P., R.J., and M.B.; Formal Analysis, N.P.; Writing – Original Draft, D.C.S., M.B., and A.C.P.; Writing – Review & Editing, all authors; Funding Acquisition, A.C.P.; Supervision, A.C.P., M.B., and S.E.L.
DATA & RESOURCE AVAILABILITY
Authors are in the process of submitting RNA sequencing data to the Gene Expression Omnibus (GEO) database of the National Center for Biotechnology Information (NCBI). Additional datasets and materials generated during the current study are available from the corresponding author on reasonable request.
SUPPLEMENTAL FIGURES
ACKNOWLEDGEMENTS
We thank Drs. Y. Kubota, S. Efrat, P. Campochiaro, and M. Gannon for providing mice. We are grateful to Drs. A. Pozzi, A. Hatzopoulos, D. Jacobson, R. Stein, P. Kendall, J. Thomas, V. Babaev, P. Young, and Y. Dor for helpful discussions. This work was supported by grants from the Department of Veterans Affairs, the JDRF, the NIH (DK106755, DK89572, DK66636, DK69603, DK63439, DK62641, DK72473, DK94199, DK68764, DK97829, DK11232, DK117147, DK104211), and the Vanderbilt Diabetes Research and Training Center (DK20593). Islet isolation was performed in the Vanderbilt Islet Procurement and Analysis Core (DK20593). Image acquisition was performed in part through use of the Vanderbilt Cell Imaging Shared Resource (CA68485, DK20593, DK58404, DK59637, EY08126) and Vanderbilt Islet Procurement and Analysis Core (DK20593). Flow cytometry was performed in the Vanderbilt Flow Cytometry Shared Resource (P30 CA68485, DK058404). Cd5-CreER mouse line rederivation was performed by the Vanderbilt Genome Editing Resource of the Center for Stem Cell Biology (CA68485, DK20593).
REFERENCES
- 1.↵
- 2.
- 3.
- 4.↵
- 5.↵
- 6.↵
- 7.
- 8.↵
- 9.↵
- 10.↵
- 11.↵
- 12.↵
- 13.↵
- 14.
- 15.
- 16.↵
- 17.↵
- 18.↵
- 19.↵
- 20.↵
- 21.
- 22.↵
- 23.↵
- 24.↵
- 25.↵
- 26.↵
- 27.↵
- 28.↵
- 29.↵
- 30.↵
- 31.↵
- 32.↵
- 33.↵
- 34.↵
- 35.
- 36.
- 37.↵
- 38.↵
- 39.
- 40.↵
- 41.↵
- 42.↵
- 43.↵
- 44.↵
- 45.
- 46.↵
- 47.↵
- 48.↵
- 49.
- 50.↵
- 51.↵
- 52.
- 53.
- 54.↵
- 55.↵
- 56.↵
- 57.
- 58.↵
- 59.↵
- 60.↵
- 61.
- 62.↵
- 63.↵
- 64.
- 65.
- 66.↵
- 67.↵
- 68.↵
- 69.↵
- 70.
- 71.
- 72.↵
- 73.↵
- 74.
- 75.↵
- 76.↵
- 77.
- 78.
- 79.
- 80.↵
- 81.↵
- 82.↵
- 83.↵
- 84.↵
- 85.↵
- 86.↵
- 87.↵
- 88.↵